Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database (CHARMD)

IF 4.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Antiviral research Pub Date : 2024-09-28 DOI:10.1016/j.antiviral.2024.106016

Valentin Tilloy , Daniel Díaz-González , Lisa Laplace , Emilien Bisserier , Sunwen Chou , William D. Rawlinson , Guy Boivin , Fausto Baldanti , Tiziana Lazzarotto , Graciela Andrei , Hans H. Hirsch , María Ángeles Marcos , Detlef Michel , Sébastien Hantz , Sophie Alain

{"title":"Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database (CHARMD)","authors":"Valentin Tilloy , Daniel Díaz-González , Lisa Laplace , Emilien Bisserier , Sunwen Chou , William D. Rawlinson , Guy Boivin , Fausto Baldanti , Tiziana Lazzarotto , Graciela Andrei , Hans H. Hirsch , María Ángeles Marcos , Detlef Michel , Sébastien Hantz , Sophie Alain","doi":"10.1016/j.antiviral.2024.106016","DOIUrl":null,"url":null,"abstract":"<div><div>A comprehensive and accessible Herpesvirus drug resistance database was designed to serve as an international reference for diagnosis and clinical studies. This database available at <span><span>https://www.unilim.fr/cnr-herpesvirus/outils/codexmv/</span><svg><path></path></svg></span>includes both resistance-related mutations and natural polymorphisms. Initially designed for human cytomegalovirus, it will be expanded to include herpes simplex and varicella-zoster viruses. Newly published mutations and new mutations reported by users or collaborating expert laboratories will be reviewed by an international committee of reference laboratories before inclusion in the database. Coupled with the Herpesvirus Sequence Analysis tool (HSA) mutation reports from NGS or Sanger sequences, it will be an open source for researchers in the field of Herpesviruses. We hope to fill this unmet need for the development and standardization of resistance genotyping.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"231 ","pages":"Article 106016"},"PeriodicalIF":4.5000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0166354224002250","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

A comprehensive and accessible Herpesvirus drug resistance database was designed to serve as an international reference for diagnosis and clinical studies. This database available at https://www.unilim.fr/cnr-herpesvirus/outils/codexmv/includes both resistance-related mutations and natural polymorphisms. Initially designed for human cytomegalovirus, it will be expanded to include herpes simplex and varicella-zoster viruses. Newly published mutations and new mutations reported by users or collaborating expert laboratories will be reviewed by an international committee of reference laboratories before inclusion in the database. Coupled with the Herpesvirus Sequence Analysis tool (HSA) mutation reports from NGS or Sanger sequences, it will be an open source for researchers in the field of Herpesviruses. We hope to fill this unmet need for the development and standardization of resistance genotyping.

查看原文本刊更多论文

疱疹病毒抗病毒药物耐药性突变综合数据库（CHARMD）。

疱疹病毒耐药性数据库设计全面、易于访问，可作为诊断和临床研究的国际参考资料。该数据库可在 https://www.unilim.fr/cnr-herpesvirus/outils/codexmv/ 上查阅，其中包括与耐药性相关的突变和自然多态性。该数据库最初是为人类巨细胞病毒设计的，随后将扩展到单纯疱疹病毒和水痘-带状疱疹病毒。新发表的变异和用户或合作专家实验室报告的新变异将由参考实验室国际委员会进行审查，然后纳入数据库。该数据库与疱疹病毒序列分析工具（HSA）的 NGS 或 Sanger 序列突变报告相结合，将成为疱疹病毒领域研究人员的开放源。我们希望能满足耐药性基因分型的开发和标准化方面的这一尚未满足的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral research 医学-病毒学

CiteScore

17.10

自引率

3.90%

发文量

157

审稿时长

34 days

期刊介绍： Antiviral Research is a journal that focuses on various aspects of controlling viral infections in both humans and animals. It is a platform for publishing research reports, short communications, review articles, and commentaries. The journal covers a wide range of topics including antiviral drugs, antibodies, and host-response modifiers. These topics encompass their synthesis, in vitro and in vivo testing, as well as mechanisms of action. Additionally, the journal also publishes studies on the development of new or improved vaccines against viral infections in humans. It delves into assessing the safety of drugs and vaccines, tracking the evolution of drug or vaccine-resistant viruses, and developing effective countermeasures. Another area of interest includes the identification and validation of new drug targets. The journal further explores laboratory animal models of viral diseases, investigates the pathogenesis of viral diseases, and examines the mechanisms by which viruses avoid host immune responses.